Fabry's disease pathophysiology: Difference between revisions

Jump to navigation Jump to search
Ghsanadgol (talk | contribs)
Ghsanadgol (talk | contribs)
Line 10: Line 10:


*[[GLA|GLA gene]] codes information for the [[Alpha-galactosidase|alpha- galactosidase]] enzyme.
*[[GLA|GLA gene]] codes information for the [[Alpha-galactosidase|alpha- galactosidase]] enzyme.
*Normal function of the enzyme [[alpha-galactosidase]] is to breakdown [[Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase|globotriaosylceramide]] (also abbreviated as [[Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase|Gb3, GL-3, or ceramide trihexoside]]) into [[glucocerebroside]] in [[lysosomes]].
*Normal function of the [[alpha-galactosidase]] enzyme  is to breakdown [[Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase|globotriaosylceramide]] (also abbreviated as [[Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase|Gb3, GL-3, or ceramide trihexoside]]) into [[glucocerebroside]] in [[lysosomes]].
*Gb3 is produced by catabolism of [[Globoside]], am essential [[glycophingolipids]] of the cells' membrane ([[RBC]]s and Kidney)
*[[Gb3]] is produced by catabolism of [[Globoside]], an essential [[glycophingolipids]] of the cells' membrane ([[RBC]]s and Kidney),that mainly metabolized in the lysosome of [[spleen]], [[liver]] and [[bone marrow]].
*Globoside is mainly metabolized in the lysosome of [[spleen]], [[liver]] and [[bone marrow]].


====Pathogenesis====
====Pathogenesis====

Revision as of 21:28, 12 March 2022

Fabry's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fabry's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fabry's disease pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fabry's disease pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fabry's disease pathophysiology

CDC on Fabry's disease pathophysiology

Fabry's disease pathophysiology in the news

Blogs on Fabry's disease pathophysiology

Directions to Hospitals Treating Fabry's disease

Risk calculators and risk factors for Fabry's disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sukaina Furniturewala, MBBS[2]

Overview

Pathophysiology

Physiology

Pathogenesis

Genetics

Gross pathology

Microscopic pathology

On histopathological analysis, these findings are characteristic of Fabry's disease:

  • light microscopy is not as specific in confirming FD as electron microscopy and thus is only done when electron microscopy is unavailable. Lipid staining of a kidney biopsy may demonstrate storage cells within the glomeruli, which proves of little significance.
  • Ultrastructural analysis of the heart and kidney biopsies can reveal lysosomal storage in the endomyocardial and certain renal tubular cells respectively. The ultrastructural appearance of these inclusions is whorled layers of alternating dense and pale material also called zebra bodies.


References